More articles from Departments

  • Correction
    Cleveland Clinic Journal of Medicine March 2012, 79 (3) 222;
  • Reviewers 2011
    Cleveland Clinic Journal of Medicine March 2012, 79 (3) 192;
  • Cervical cancer screening (November 2011)
    David L. Keller, MD
    Cleveland Clinic Journal of Medicine March 2012, 79 (3) 164; DOI: https://doi.org/10.3949/ccjm.79c:03001

    Readers comment on the oral anticoagulant dabigatran (October 2011), and screening for cervical cancer (November 2011).

  • In reply: Dabigatran (October 2011)
    Siddharth A. Wartak, MD and John R. Bartholomew, MD
    Cleveland Clinic Journal of Medicine March 2012, 79 (3) 168-169; DOI: https://doi.org/10.3949/ccjm.79c:03005
  • Dabigatran (October 2011)
    Patricio A. Pazmiño, PhD, MD, FACP, FASN
    Cleveland Clinic Journal of Medicine March 2012, 79 (3) 166; DOI: https://doi.org/10.3949/ccjm.79c:03003

    Readers comment on the oral anticoagulant dabigatran (October 2011), and screening for cervical cancer (November 2011).

  • In reply: Cervical cancer screening (November 2011)
    Xian Wen Jin, MD, PhD, FACP and Andrea Sikon, MD
    Cleveland Clinic Journal of Medicine March 2012, 79 (3) 164; DOI: https://doi.org/10.3949/ccjm.79c:03002
  • Correction
    Cleveland Clinic Journal of Medicine January 2012, 79 (1) 78; DOI: https://doi.org/10.3949/ccjm.79c.01001
  • In reply: Dabigatran (October 2011)
    Siddharth A. Wartak, MD and John R. Bartholomew, MD, FACC
    Cleveland Clinic Journal of Medicine December 2011, 78 (12) 787; DOI: https://doi.org/10.3949/ccjm.78c.12002
  • In reply: The negative U wave in the setting of demand ischemia (August 2011)
    Sridhar Venkatachalam, MD, MRCP and Curtis M. Rimmerman, MD, MBA
    Cleveland Clinic Journal of Medicine December 2011, 78 (12) 785; DOI: https://doi.org/10.3949/ccjm.78c:12004
  • Dabigatran (October 2011)
    Van Smith, MD, FACP
    Cleveland Clinic Journal of Medicine December 2011, 78 (12) 787; DOI: https://doi.org/10.3949/ccjm.78c.12001

    Readers comment on negative U waves (August 2011) and on dabigatran (October 2011).

Pages